CAFs-Derived Lactate Drives Oxaliplatin Resistance in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer mortality, with chemotherapy—particularly oxaliplatin—being a mainstay for advanced and metastatic disease. Despite the therapeutic success of oxaliplatin, a significant subset of patients either fails to respond or develops resistance, leading to poor prognosis and frequent disease recurrence. Previous research suggests that the tumor microenvironment, and specifically cancer-associated fibroblasts (CAFs), play a pivotal role in sustaining cancer stemness and therapy resistance. The central research question in the recent Cancer Letters study was: how do CAFs contribute to oxaliplatin resistance in CRC, and what molecular mechanisms underlie this process?

Key Innovation from the Reference Study

The principal innovation of this study lies in delineating the mechanistic axis by which CAFs, via glycolysis-derived lactate, induce resistance to oxaliplatin chemotherapy in CRC cells. Specifically, the authors provide evidence that lactate produced by CAFs is taken up by cancer cells, where it orchestrates both histone lactylation and direct lactylation of the anthrax toxin receptor 1 (ANTXR1) at lysine 453. This dual lactylation enhances the expression and stability of ANTXR1, promoting cancer stem cell (CSC) properties and activating the RhoC/ROCK1/SMAD5 pathway, ultimately leading to chemoresistance. The work thus identifies the CAF-cancer cell lactate shuttle and ANTXR1 lactylation as critical drivers of oxaliplatin resistance.

Methods and Experimental Design Insights

The investigators employed a comprehensive suite of in vitro and in vivo approaches to dissect the CAF–CRC cell interaction:

• CAF isolation and characterization from clinical CRC samples, followed by metabolic profiling to confirm enhanced glycolytic activity and lactate secretion.
• Co-culture systems (including patient-derived xenografts and organoids) to model stromal–epithelial metabolic crosstalk and its impact on drug response.
• Manipulation of lactate export/import using pharmacologic inhibitors and genetic knockdown strategies to block the CAF–cancer cell lactate shuttle.
• Chromatin immunoprecipitation and mass spectrometry to detect histone and protein lactylation, with a focus on ANTXR1 modifications.
• Gene expression analysis and protein quantification (western blot, immunofluorescence) to assess stemness markers (LGR5, CD133, CD44) and key pathway activation.
• Functional assays (sphere formation, colony formation, drug sensitivity) to quantify stemness and chemoresistance phenotypes.
• Validation in cell- and patient-derived xenograft models to confirm the clinical relevance of the findings.

This rigorous, multi-faceted design allowed the authors to triangulate the lactate–ANTXR1–RhoC/ROCK1/SMAD5 axis as a key mechanism behind oxaliplatin resistance.

Core Findings and Why They Matter

The study’s central findings are as follows:

• CAFs in CRC exhibit elevated glycolytic flux, resulting in high extracellular lactate production.
• Exposure of CRC cells to CAF-derived lactate induces both histone lactylation (which enhances ANTXR1 gene transcription) and direct lactylation of ANTXR1 at lysine 453 (K453la), stabilizing the protein.
• Elevated levels of ANTXR1 and its lactylated form are associated with increased expression of CSC markers and correlate with oxaliplatin resistance and poor patient prognosis.
• Lactylation-driven stabilization of ANTXR1 activates the RhoC/ROCK1/SMAD5 signaling pathway, reinforcing cancer stemness and survival under chemotherapeutic stress.
• Disruption of the lactate shuttle—either by blocking monocarboxylate transporters or targeting glycolysis in CAFs—restores chemosensitivity in CRC models both in vitro and in vivo.

These insights provide a mechanistic link between stromal metabolism, post-translational protein modification, and therapeutic resistance. Importantly, they suggest that targeting CAF metabolic output or lactate transport might enhance the efficacy of oxaliplatin and potentially other chemotherapeutics in CRC.

Comparison with Existing Internal Articles

Several internal resources contextualize the technical requirements for advanced tumor microenvironment models and chemoresistance studies:

• Beyond Routine DNA Removal: DNase I (RNase-free) as a Strategic Tool highlights the necessity of precise nucleic acid purification—especially in complex organoid–fibroblast co-culture systems similar to those employed in the reference study. The article underscores how accurate DNA removal for RNA extraction is crucial when profiling gene expression in models recapitulating stromal-driven drug resistance.
• DNase I (RNase-free): Precision DNA Removal for RNA Extraction discusses how specialized, ribonuclease-free DNase I enables clean separation of RNA from DNA in stroma-rich samples, a key consideration when measuring transcriptional responses or stemness markers after CAF–CRC interaction.
• Mechanistic and workflow discussions in DNase I (RNase-free): Precision Endonuclease for DNA Removal further reinforce the importance of robust DNA removal for reproducible RT-PCR and chromatin digestion, particularly in translational oncology research.

Compared to these discussions, the reference study advances the field by directly linking the functional output of CAF metabolism to post-translational protein modifications and clinical drug response, rather than focusing solely on technical workflow optimization. However, the internal articles collectively illustrate the foundational importance of high-fidelity DNA removal and RNA analysis in enabling such mechanistic discoveries.

Limitations and Transferability

Despite its strengths, the study has several limitations:

• The reliance on in vitro and xenograft models, while informative, may not fully recapitulate the complexity of the human tumor microenvironment, including immune and vascular components.
• Although the lactate–ANTXR1 axis is shown to drive resistance to oxaliplatin, its role in resistance to other chemotherapeutics remains to be explored.
• Targeting lactate shuttling or ANTXR1 lactylation in vivo may present off-target effects, and the safety profile of such interventions is yet to be established.
• Patient heterogeneity, including differences in CAF subtypes and metabolic plasticity, may influence the generalizability of these findings to broader CRC populations.

Nonetheless, the demonstration that pharmacologic inhibition of CAF-derived lactate or lactate import re-sensitizes CRC models to oxaliplatin provides a strong rationale for translational studies and possible clinical trials.

Protocol Parameters

• CAF isolation and co-culture: Primary CAFs were isolated from CRC patient tissue and co-cultured with CRC cell lines or organoids for 48–72 hours to model stromal influence.
• Lactate shuttle inhibition: Monocarboxylate transporter inhibitors (e.g., CHC) were applied at 5–10 mM concentrations to block lactate export/import during co-culture experiments.
• Drug sensitivity assays: Oxaliplatin was administered at 2–10 μM for 24–72 hours to measure cell viability and chemoresistance in the presence or absence of CAF-derived lactate.
• ANTXR1 lactylation detection: Immunoprecipitation and mass spectrometry protocols included 1–2 μg protein input and detection of lysine lactylation at K453.
• RNA extraction and DNA removal: Use of ribonuclease-free DNase I is recommended for eliminating genomic DNA contamination prior to RT-qPCR when measuring transcriptional responses.

Research Support Resources

For researchers aiming to replicate or extend these findings—particularly those performing RNA extraction from complex tumor models or stroma-rich samples—precise removal of contaminating DNA is essential for accurate gene expression analysis and in vitro transcription sample preparation. DNase I (RNase-free) (SKU K1088) from APExBIO is widely used as an endonuclease for DNA digestion in workflows where ribonuclease-free conditions are critical, such as the removal of DNA contamination in RT-PCR and chromatin digestion enzyme applications. This resource supports the fidelity required for next-generation molecular oncology studies, as demonstrated in the referenced and internal literature.